AzTrials
AzTrials

AgingNCT06203392

Effects of a Very Low Carbohydrate Ketogenic Diet or Mediterranean Diet on Markers of Musculoskeletal Health in Older Adults

A study testing Very low carbohydrate ketogenic diet and Mediterranean diet in people with Aging and Musculoskeletal Diseases, run by University of Florida at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Preclinical data indicate that very low carbohydrate ketogenic diets (KD) may prevent progression of age-related sarcopenia (skeletal muscle decline) but also may disturb bone metabolism. Read more about this study

Who is it for?
Ages 55 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Aging, Musculoskeletal Diseases
What is being tested?
Very low carbohydrate ketogenic diet and Mediterranean diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
15 Jul 2024to 24 Nov 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Postmenopausal
  • BMI 20 to <40 kg/m2
  • Weight stable for last 12 months
  • Male or female biological sex
  • Willing to eat supplied food and adhere to dietary advice
  • Willing to document food intake
Show all 15Show fewer
  • Willing to maintain weight
  • Willing to attend study visits
  • Smartphone ownership
  • Community-dwelling with permanent living arrangement
  • Resides within 30 miles of Gainesville, FL
  • Willing to avoid alcohol intake
  • Estimated energy requirement ≤ 2,700 kcal/day
  • Have a refrigerator and means to reheat food within dwelling
  • Bone mineral density tested within past 5 years or U.S. ethnicity-specific fracture risk assessment tool (FRAX) indicates ten year-probability of hip fracture <3% and ten year-probability of major osteoporotic fracture <20%

Who cannot join

  • Pre- or peri-menopausal
  • Fracture in past 6 months
  • Circulating 25-hydroxyvitamin D < 20 ng/mL at screening
  • History or prevalence of metabolic bone disease
  • Chronic kidney disease diagnosis or eGFR <60 mL/min/1.73 m2 at screening
  • Current or history of cancer excluding non-melanoma skin cancer
Show all 32Show fewer
  • Clinical cardiovascular disease, excluding current use of anti-hypertensive medication
  • LDL cholesterol at screening that is elevated (≥ 160 mg/dL) or uncontrolled (≥ 100 mg/dL despise current statin treatment)
  • History of recurrent kidney stones
  • Current diabetes diagnosis
  • Liver disease
  • Pancreatic disease
  • Heavy drinking per CDC definition
  • Currently smoke tobacco
  • Malabsorption disease including celiac and inflammatory bowel disease
  • Inborn error of metabolism including disorders of fatty acid transport or oxidation, organic aciduria, porphyria, or familial hyperlipidemia
  • Dementia diagnosis
  • Dietary restrictions including food allergy, vegetarianism, veganism or gluten, dairy, or seafood avoidance
  • Current or history of diagnosed eating disorder
  • Thyroid disorder
  • Male hypogonadism
  • Menopause before age 40 years
  • Gender-affirming hormone therapy
  • Currently eat a ketogenic or Mediterranean diet based on ASA 24-hour dietary recall and Mediterranean diet screener
  • Participation in concurrent research study
  • Currently homeless
  • Presence or possibility of co-morbid condition discovered during medical screening that would elicit safety concerns
  • Living in skilled nursing facility
  • Current gallbladder disease including gallstones
  • History of 2 or more abdominal surgeries
  • Current chronic constipation
  • Current chronic diarrhea

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Florida

    Gainesville, Florida, 32610

Other trials in United States

About this study

Official title: Effects of a Very Low Carbohydrate Ketogenic Diet Versus Mediterranean Diet on Markers of Bone Health and Muscle Function in Older Adults: A Pilot Study

Preclinical data indicate that very low carbohydrate ketogenic diets (KD) may prevent progression of age-related sarcopenia (skeletal muscle decline) but also may disturb bone metabolism. The investigators will pilot test a randomized trial comparing the effects of short-term adaptation to a well-formulated ketogenic diet and Mediterranean diet on markers of bone metabolism and muscle function in older adults. The expected results will help inform the benefit-risk assessment for older patients considering longer term use of KD therapy.

Read the detailed description

Eucaloric very low carbohydrate ketogenic diets (KD) are therapeutic diets that mimic fasting by generating ketones for metabolic fuel while meeting nutritional requirements (nutritional ketosis). Nutritional ketosis may broadly benefit healthspan through mechanisms such as suppression of inflammation or induction of autophagy, and preclinical and emerging clinical data indicate that KD therapy may help slow progression of age-related conditions including sarcopenia. However, questions remain about the benefits and risks of KD, especially relative to recommended therapeutic diets such as the Mediterranean Diet (MD) for which there is evidence of benefit for age-related conditions. For example, KD has shown efficacy for weight loss, which could reduce ectopic lipid accumulation that weakens muscle and bone. KD has been shown to increase skeletal muscle mitochondrial mass, mitochondrial activity, and strength in aged mice, possibly by increasing peroxisome proliferator-activated receptor activity and preserving fast-oxidative fibers that typically decline with age. However, long term use of KD may adversely impact bone. KD can cause deterioration of bone in juvenile mice without evidence of undernutrition and is associated with skeletal demineralization in children being treated for drug-resistant epilepsy.

Given the burden of musculoskeletal disease in older Americans, it is vital to understand the effects of KD on the musculoskeletal system of older adults to inform the benefit-risk assessment for an older patient and to optimize the effectiveness of KD for age-related conditions. The investigators are conducting a pilot test of a randomized clinical trial comparing the effects of short-term adaptation to a well-formulated KD and MD on markers of bone health and muscle function in older adults. The investigators will supply fresh prepared meals to achieve high adherence to the dietary interventions and adequate contrast in metabolic state between treatment groups.

Potential participants will complete a screening process so the investigators can determine whether potential participants are eligible to enroll in the study. At the first screening visit, the study team will measure blood pressure, height, and weight. Individuals will complete questionnaires that collect information about their health history, dietary intake, and physical activity habits. No more than 50 mL of blood will be collected from potential participants to run routine clinical lab tests to evaluate health status.

If an individual remains eligible after the first screening visit, they will be invited to complete a 24-hour urine collection (at home) and to schedule a second screening visit. At the second screening visit, a physician will conduct a physical exam and assess their body composition with an x-ray technology called dual-energy x-ray absorptiometry (DEXA or DXA).

If an individual remains eligible after the second screening visit, they will be invited to enroll in the dietary intervention study. Once enrolled, the participant will be assigned to either a very low carbohydrate ketogenic dietary pattern or a Mediterranean dietary pattern. The investigators will provide most of the food the participant will need each day in the form of a nutrition shake (breakfast) and two prepared meals (lunch and dinner). A study dietitian will be available to provide continuous support through a secure messaging app.

While in the dietary intervention phase of the study, participants will come to the UF Clinical and Translational Science Building once a week for 6 weeks. The study team will measure participant blood pressure and weight at each visit. At the first, middle, and final visits, the study team will collect a blood sample and urine sample from participants for lab testing, and participants will complete a short series of tests that measure physical performance.

Our ultimate research goal is to determine the effects of KD on body composition and clinically relevant measures of bone health and muscle function, as those data are needed to (1) inform the benefit-risk assessment for an older patient who is considering longer term adherence to KD therapy and (2) optimize the effectiveness of KD for age-related conditions.

Being tested
Very low carbohydrate ketogenic diet, Mediterranean diet
Keywords
diet, aging, ketogenic, ketosis, Mediterranean
Medical subject headings
Musculoskeletal Diseases, Ketosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Very low carbohydrate ketogenic dietOther

    Very low carbohydrate ketogenic diet provided for six weeks

  • Mediterranean dietOther

    Mediterranean diet provided for six weeks

Study groups in NCT06203392
Study groupRoleWhat they receive
Very low carbohydrate ketogenic diet for six weeksExperimentalNot described
Receives: Other: Very low carbohydrate ketogenic diet
Mediterranean diet for six weeksActive comparatorNot described
Receives: Other: Mediterranean diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of enrollment

    Number of participants enrolled in dietary intervention phase per month

    Measured: Monthly. Up to 24 months.

  2. Screen failure rate (percentage)

    Number of participants deemed ineligible / number of participants screened * 100

    Measured: Monthly. Up to 24 months.

  3. Treatment-specific retention rates

    Percentage of participants enrolled in dietary intervention phase who complete at least 6 intervention study visits including baseline, middle, and final visit.

    Measured: Either after the endline visit or when participant is withdrawn or withdraws from study

Secondary outcomes (1)
  1. Treatment-specific adherence rates

    Treatment-specific adherence rates to protocol as evidenced by (1) dietary intake (2) blood ketone concentrations

    Measured: Either after the endline visit or when participant is withdrawn or withdraws from study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2024
  2. Study start15 Jul 2024
  3. Primary completion24 Nov 2025
  4. Study completion24 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06203392
Sponsor's protocol ID
IRB202301329
Other IDs
2P30AG028740-16
Status last verified
Dec 2025
First submitted
1 Nov 2023
Last updated
28 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD will be shared upon reasonable request

Questions about this trial

What is this clinical trial studying?

A study testing Very low carbohydrate ketogenic diet and Mediterranean diet in people with Aging and Musculoskeletal Diseases, run by University of Florida at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of enrollment (time frame: Monthly. Up to 24 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in